HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2025
0mins
Source: Globenewswire
SAVANNAH Phase II Trial Results: The SAVANNAH Phase II trial showed that the combination of savolitinib and TAGRISSO® resulted in a significant objective response rate of 56% in patients with advanced MET-high NSCLC who had previously progressed on TAGRISSO®, indicating a promising treatment option without chemotherapy.
Survival Benefits from Savolitinib Phase IIIb Study: Updated results from a Phase IIIb study demonstrated long-term survival benefits for patients with MET exon 14 mutation NSCLC treated with savolitinib, particularly in treatment-naïve patients, with median overall survival rates of 28.3 months and 25.3 months for treatment-naïve and previously treated patients, respectively.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
